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Low nicotinamide mononucleotide adenylyltransferase
activity in a tiazofurin-resistant cell line: effects on NAD
metabolism and DNA repair
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Summary Poly(ADP-ribose) polymerase (PADPRP), which uses NAD to synthesize ADP-ribose polymers, is activated by DNA strand
breaks and mediates cellular responses to DNA damage. The consequences of low cellular NAD levels in a cell line deficient in nicotinamide
mononucleotide adenylyltransferase (NMNAT), an enzyme essential for NAD biosynthesis, were investigated by assessing NAD metabolism
and DNA repair after treatment with alkylating agents. A tiazofurin-resistant L1210 cell line (TZR) was isolated. NAD levels were
approximately 5933 and 3375 pmol mg-1 protein for parental (wild type, WT) and TZR cells respectively, and NMNAT levels were reduced by
> 95%. TZR cells were more sensitive to temozolomide (TM) and 1-methyl-3-nitro-1-nitroso-guanidine (MNNG), particularly at concentrations
that caused > 50% NAD depletion. TM and MNNG treatment decreased NAD levels in both cell lines, buttook longerto return to control levels
in TZR cells. For example, MNNG (5gM), depleted NAD levels at 6 h to approximately 4512 (WT) and 1442 (TZR) pmol mg-1 protein;
however, NAD levels had returned to control levels by 8 h in WT cells, but were not restored by 16 h in TZR cells. Both cell lines were
equisensitive to the growth-inhibitory effects of NU1025 per se (IC50 370 ,UM). Co-exposure of the cell lines to TM (100gM) with increasing
concentrations of NU1025 led to a synergistic enhancement of cytotoxicity, with IC50 values for NU1025 decreasing to 17 ± 4,gM (TZR) and
37 ± 6gM (WT). A similar enhanced sensitivity to NU1025 (approximately 2.7-fold) was obtained when TZR cells were co-exposed to
MNNG + NU1025. TM-induced DNA strand breaks were increased by co-incubation with NU1025, and again the TZR cell line showed
increased sensitivity to NU1025. There were no significant changes in NMNATactivity in response to MNNG treatment over 24 h, either in the
presence or in the absence of NU1025. These data demonstrate that modest decreases in cellular NAD levels can sensitize cells to alkylating
agents and PADPRP inhibitors.
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Poly(ADP-ribose) polymerase (PADPRP EC 2.4.2.30) uses NAD
as substrate to modify covalently both itself and associated chro-
matin proteins with long, branched ADP-ribose homopolymers
(for reviews, see Lautier et al, 1993; de Murcia and Menissier-de
Murcia, 1994). PADPRP binds strongly to, and is activated by,
DNA ends. The immediate and extensive synthesis ofADP-ribose
polymers at the sites of DNA strand breaks constitutes a rapid
stress response to DNA damage in eukaryotic cells (see Lindahl et
al, 1995). However, the exact function ofthis response remains to
be elucidated.
Inhibitors of PADPRP potentiate the cytotoxicity of a range of
DNA-damaging agents that cause damage repaired mainly by the
base excision repair pathway (e.g. Durkacz et al, 1980). It is
assumed that the enhanced cytotoxicity is caused by the transient
inhibition of DNA strand break rejoining that occurs. PADPRP
function may actively mediate base excision repair, for example
by relaxation of chromatin at the site of the DNA strand break,
thus facilitating the access ofrepair enzymes (Althaus et al, 1993).
Alternatively, the retardation of repair by PADPRP inhibitors
could be an artefactual consequence of the sequestration of DNA
ends from repair enzymes by the bound inactivated enzyme,
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unable to detach because it cannot be automodified by poly-
(ADP-ribosylation). Overproduction of the PADPRP DNA-
binding domain in cells, which presumably mimics the inhibited
enzyme, also blocks alkylation-induced DNA repair (Molinette
et al, 1993).
To test the hypothesis that modulation of NAD synthesis could
affect the cellular response to DNA damage by altering substrate
availability forPADPRP and/orexacerbating NAD depletion, acell
line with low NAD levels, resulting from a deficiency in nicotin-
amide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1)
function, was isolated. NMNAT is the final enzyme in the biosyn-
thesis ofNAD: NMN + ATP -* NAD + PPi. A possible functional
interdependence of PADPRP and NMNAT is exemplified by their
co-location to the nuclear matrix (e.g. Kaufmann et al., 1991;
Balducci et al., 1992). The cell line was selected by continuous
exposure to increasing concentrations of tiazofurin (TZ). TZ
(2-,-D-ribofuranosylthiazole-4-carboxamide) is converted to an
analogue of NAD (TAD) in which the thiazole-4-carboxamide
moiety replaces nicotinamide (Jayaram et al., 1982). TAD is a
potent inhibitor of IMP dehydrogenase (Cooney et al, 1982).
Resistance to TZ in cell lines (e.g. Jayaram et al., 1993) arises
predominantly through loss of function of NMNAT, which is
essential for the anabolism ofTZ to TAD.
Depleting NAD by starving cells of nicotinamide has been
demonstrated to sensitize cells to DNA-damaging agents (Durkacz
et al., 1980; Jacobson et al., 1992). A 40% depletion in NAD
levels sufficed to substantially reduce carcinogen-stimulated
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ADP-polymer synthesis. Another possible consequence of
reduced NAD content is that high levels of PADPRP activation,
which causes severe NAD depletion, could cause 'cellular
suicide', as first postulated by Berger (1985). Extensive NAD
depletion, and the ensuing ATP depletion (Cohen and
Barankiewicz, 1987), can lead to cell death that is abrogated by
PADPRP inhibition, despite the concurrent inhibition of DNA
repair. For example, neuronal cells and pancreatic islet cells
exposed to the free radical nitric oxide, which is produced in
inflammatory responses, causes DNA damage and PADPRP acti-
vation (Radons et al., 1994; Zhang etal., 1994; Helleret al., 1995).
The use of PADPRP inhibitors, or PADPRP-negative cells,
prevents the NAD depletion and reduces cytotoxicity.
A substantive body of literature demonstrates that PADPRP
inhibitors modulate repair and survival in DNA-damaged cells.
Furthermore, PADPRP-negative mice appear normal (apart from
skin lesions in older mice), indicating that the enzyme has no
essential role in unstressed metabolism (Wang et al., 1995), and
thus PADPRP inhibitors would be predicted to exert no non-
specific cytotoxic effects. Therefore, novel potent inhibitors have
been recently developed with a view to using them as resistance
modifiers in conjunction with anti-cancer drugs that damage DNA
(Suto et al., 1991; Griffin et al., 1995). However, little work has
been carried out to assess factors such as NAD metabolism that
could modulate both PADPRP function in cells and/or the cellular
response to PADPRP inhibitors.
This current investigation analysed the activity ofNMNAT and
the consequences ofdefective NAD biosynthesis on cellular NAD
levels in the tiazofurin-resistant cell line, with specific attention to
its chemosensitivity and DNA repair ability. Two monofunctional
alkylating agents, l-methyl-3-nitro-1-nitroso-guanidine (MNNG)
and temozolomide (TM) (Stevens et al., 1987), were used in the
study. TM, which has shown promising results in phase I clinical
trials (Newlands et al., 1992), breaks down to 3-methyl-9triazen-
1-yl)imidazole-4-carboxamide (MTIC), which, like MNNG,
methylates bases in DNA.
A competitive inhibitor of PADPRP, NU1025 (8-hydroxy-2-
methylquinazolin-4-one), (Griffin et al., 1995), was also used in
these studies. NU1025 has an IC50 value for PADPRP inhibition of
0.44 ± 0.13 ,UM, compared with 19.1 ± 5.9gM for 3-aminobenz-
amide, and has proven a potent potentiator of monofunctional
alkylating agent cytotoxicity in cell culture, and an inhibitor of
single-strand DNA strand break repair (Boulton et al, 1995).
MATERIALS AND METHODS
Drugs and chemicals
TZ and TM were kindly provided by Dr V Narayanan, National
Cancer Institute, Bethesda, MD, USA, and Professor MFG
Table 1 Characterization of cell lines
Parameter/cell line WT TZR
NMNAT activity 401 ±27 11 ±4
PADPRP activity 206 ± 1 167 ± 3
IC50 of NU1025 0.44 ± 0.002 0.39 ± 0.04
NAD content 5933 ± 187 3375 ± 249
aEnzyme activities and NAD levels are expressed as defined in Materials and
methods.
Stevens, Cancer Research Laboratories, University of
Nottingham, UK, respectively. NU1025 was synthesized in the
Chemistry Department, University of Newcastle upon Tyne, and
the methodology is described elsewhere (Griffin et al, 1995). TM
and NU1025 were dissolved in dimethyl sulphoxide (DMSO), and
added to cell culture at final concentrations ofnot greater than 1%
DMSO. MNNG and TZ stocks were prepared in 100 mm sodium
acetate and water respectively, filter sterilized and stored in
aliquots at-20°C.
Cell culture and growth inhibition assays
The murine leukaemia L1210 cell line (hereafterreferred to as WT
for wild type) and the mutant cell line (see below) were propa-
gated in RPMI-1640 medium supplemented with 10% fetal calf
serum, glutamine (2 mM) and antibiotics (penicillin, 100 U ml-';
streptomycin, 100 ,ug ml-). Cell densities were maintained
between 1 x 104 and 8 x 105 ml-'.
Growth inhibition assays were performed exactly as described
previously (Boulton et al, 1995), with the specific drug treatment
protocols as described in the figure legends herein. Control cells
were incubated in medium + DMSO. The cells were incubated for
48 h, with or without the drugs, before counting. In drug combina-
tion experiments, in which evidence of synergistic effects on cell
growth was being sought, the single, fixed concentration drug
sample was taken as the control value. The growth ofthe 'control'
cells was expressed as 100% in either case. The graphs show the
average ± s.e. of three independently performed experiments.
Where error bars are not shown, in these and other experiments, it
is because they are obscured by the symbols. The average IC50
values, both from growth inhibition experiments and in PADPRP
assays, were calculated using the smooth curve analysis of
GraphPad Inplot (San Diego, CA, USA) software.
Isolation of the TZR cell line
The TZ-resistant cell line (TZR) was selected by exposure to step-
wise increments in TZ concentration, starting with the IC50 value
(2.7 gM), over a period of about 3 months, finally attaining a
concentration of 2 mm. A pure clonal derivative was selected by
plating for single colonies in soft agar, and picking out colonies to
be propagated in microtitre wells using the tip of a sterile Pasteur
pipette.
NMNAT assay
NMNAT activity was assayed by a modification of the technique
used by Ahluwalia et al (1984). Whole-cell sonicates (derived
from 1 x 107 cells in exponential growth phase) were prepared as
follows: cells were harvested and washed once in ice-cold phos-
phate-buffered saline, repelleted and resuspended in 1.0 ml of an
ice-cold buffer containing 20 mM Tris-HCl, pH 7.4, 1 mm dithio-
threitol. These were sonicated on ice for 10 s, amplitude 15 (MSE
Soniprep 150). An aliquot (75 ,ul) ofthe samples was removed for
protein estimation (Bradford, 1976). A total of 200 ,ul ofthe soni-
cate was used to initiate the NMNAT assay, which was carried out
exactly as described (Ahluwalia et al, 1984). This assay follows
the conversion ofadded NMN to NAD in the presence ofATP, in a
30-min incubation of the cell extract, by monitoring changes in
NAD levels of the reaction mix. Briefly, NAD is converted to
NADH, and this product was then quantitated by absorbance at
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Figure 1 The effect of increasing concentrations of TM (A) or MNNG (B) on
cell growth. 0, WT; A, TZR
340 nm. This latter technique proved to be too insensitive in our
hands to use with tissue culture samples (>108 cells required
per sample). The sensitivity of the assay was improved at least
tenfold by quantitating the NAD formed in the NAD assay
described below, and made practicable the measurement of
NMNAT in cell culture. The results are expressed as pmol NAD
formed min-1 mg-' protein.
NAD assay
Cellular NAD levels were determined by the method ofBernofsky
and Swan (1973). Cells were treated with drugs at the concentra-
tions and times specified in the figure legends. 5 x 106 cells were
harvested at 4°C, washed once with ice-cold phosphate-buffered
saline and repelleted. The pellet was resuspended in 1.0 ml 50%
(v/v) ethanol and sonicated for 20 s. An aliquot was removed
for protein estimation (Bradford, 1976), the suspension was
A B
centrifuged for 2 min in a microfuge, and the supernatant used for
NAD assays (Bernofsky and Swan, 1973). When samples from the
NMNAT reaction mix were used for NAD measurements, ethanol
was first added to a final volume of 50%. Results were expressed
as pmol NAD mg-1 protein and represent the average ± s.e. of at
least three independently drug-treated samples from one experi-
ment in which the TZR and WT cell lines were tested in parallel.
PADPRP assay
PADPRP activity was measured in a permeabilized cell assay.
Cells were rendered permeable to exogenous [32P]NAD by
exposure to hypotonic buffers and cold shock, as described by
Halldorsson et al (1978). In order to reveal total available enzyme
activity, a palindromic oligonucleotide, which forms a short
double-stranded loop with abluntend, was included in the assay at
a concentration of 20[ig ml-1 (Grube et al, 1991). The results are
expressed as pmol NAD incorporated min-m mg-1 protein.
DNA strand break assay
DNA single-strand break levels were assayed using the alkaline
elution technique ofKohn et al (1981). Cells were prelabelled with
['4C]TdR for 24 h followed by a 2-h chase in non-radioactive
medium. Internal standard cells were similarly labelled with
[3H]TdR and exposed to 300 cGy and kept on ice before loading
on the filters. Drug concentrations and exposure times are given in
the figure legends. To summarize the data obtained, the results are
expressed using the 'Relative Elution' (RE) formula of Fornace
and Little (1977), and the dose-response slopes calculated from
linear regression analysis.
RESULTS
Characterization of TZR cell line
The TZR cell line had an IC50 value for growth inhibition
following exposure to TZofapproximately 10 mm, compared with
2.7 gM for the WT (results not shown). It was stably resistant to
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Figure 2 (A) The effect of continuous exposure to increasing concentrations of NU1025 on cell growth. (B) The effect of increasing concentrations of NU1025
in conjunction with a fixed dose of TM (100gM) on cell growth. (C) The effect of increasing concentrations of NU1025 in conjunction with a fixed dose of MNNG
(0.25gM) on cell growth. 0, WT; A, TZR
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Figure 3 (A) The effect of a 4-h incubation with increasing concentrations of TM on NAD levels. *, WT; A, TZR. (B) The effect of 0.5 mmTM on NAD levels
over a 4-h time course. 0, WT; A, TZR. (C) The effect of a 1.5 mmTM on NAD levels over a 24-h time course. *, WT; A, TZR
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Figure 4 (A) the effect of a 4-h incubation with increasing concentrations of MNNG on NAD levels. 0, WT; A, TZR. (B) The effect of 2.5 or 5 gM MNNG on
NAD levels over a 24-h time course. 0, 2.5 gM MNNG, WT; (0) 5.0 gM MNNG, WT; (A) 2.5 gM MNNG, TZR; (A) 5.0 gM MNNG, TZR. (C) The effect of 10gM
MNNG on NAD levels over a 24-h time course. *, WT; A, TZR
TZ for at least 3 months in the absence of selection. The doubling
time (approximately 13 h) ofthe TZR cell line was identical to that
ofthe WT cell line, despite the low NAD levels (see below).
Table 1 shows NMNAT and PADPRP activities in the two cell
lines. The TZR cell line had lost > 95% of NMNAT function
compared with WT. Total available PADPRP activity was slightly
decreased (by approximately 19%) in the TZR cell line compared
with WT. It should be noted that the sensitivity of PADPRP to
NU1025 inhibition was not significantly different in the two cell
lines, with IC50 values of 0.44 + 0.002 gM and 0.39 ± 0.04 gM for
WT and TZR cells respectively. Also shown in Table 1 are the
NAD contents of the cells. It can be seen that the NAD levels
in TZR cells were about 57% of WT (3375 compared with
5933 pmol mg-' protein).
Growth inhibition
TZR cells were significantly more sensitive to both TM and
MNNG than WT cells (see Figure lA and iB). In both cases, this
effect was more marked at higher concentrations ofthe drugs. For
example, there was no difference in the sensitivity ofTZR and WT
cells to 3 gM MNNG, but there was an approximately four-fold
difference at 7 gM.
NU1025 per se became cytostatic to the cells at high concentra-
tions (Figure 2A), both cell lines being equisensitive to NU1025
with an IC50 value of approximately 370 gM. In marked contrast,
TZR cells were significantly more sensitive to the chemopotenti-
ating effects of increasing concentrations of NU1025 when co-
incubated with either a fixed concentration of TM (100gM) or a
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Figure 5 (A) The effect of a 1-h treatment with increasing concentrations of
TM on DNA strand break levels. *, WT; A, TZR. (B) The effect of a 1-h co-
incubation of increasing concentrations of NU1025 with a fixed concentration
of TM (150gM) on DNA strand break levels. RE values have been plotted
against increasing inhibitor concentration. *, WT; A, TZR
Table 2 NMNAT activity in WT cells treated with MNNG
Time (h) 10gM MNNG 10gM MNNG
+ 100gM NU1025
0 100±5 100±5
1 109±2 118±3
2 84±2 91±0
4 92±2 90±1
WT cells were treated with 10gM MNNG for different times in the presence or
absence of 100gM NU1025. Cells were harvested, and whole-cell sonicates
prepared for NMNAT assay. Results are expressed as a percentage of
control (untreated) NMNAT activity.
fixed concentration of MNNG (0.25 gM) (Figure 2B and C). As
predicted from previous results (Boulton et al, 1995), co-incuba-
tion with 100gM TM (which alone reduced survival by approxi-
mately 25%, normalized to 100% in the figure) resulted in a
dose-dependent synergistic enhancement of growth inhibition by
NU1025, but the IC50 values for NU1025 were now significantly
different between the two cell lines, being reduced to 17 ± 4 and
37 ±6gM for TZR and WT respectively (Figure 2b). The TZR cell
line also maintained this enhanced sensitivity compared with WT
to the chemopotentiating effects of increasing concentrations of
NU1025 when co-incubated with a fixed concentration ofMNNG
(0.25 tM) (Figure 2C). Here, the IC50 values were reduced to
61 ± 2gM (TZR) and 168 ± 12gM (WT). It should be stressed
these 2- and 2.7-fold differences (in TM- and MNNG-treated cells
respectively) in the sensitivity to NU1025 between the two cell
lines is only apparent when NU1025 is used in conjunction with
alkylating agents; otherwise the cells were equisensitive to the
growth-inhibitory effects of the 2 tenfold higher concentrations
of NU1025 per se (see above). In all the experiments using
TM ± NU1025, clonogenic survival experiments gave very similar
results to the growth inhibition experiments (results not shown).
NAD metabolism
Figure 3A shows a similar dose-dependent depletion following a
4-h treatment with temozolomide forboth cell lines. Figure 3B and
C shows the kinetics of the NAD depletion and recovery for
0.5 mM (3B) and 1.5 mM (3C) TM respectively. NAD levels
reached their lowest level between 4 and 8 h in WT cells (e.g.
approximately 50% of control levels at 4 h in cells treated with
1.5 mmTM), and recovered thereafter. In the 0.5 mM-treated cells,
there was areproducible 'overshoot' in NAD levels (by about 30%
at 16 h) before levels returned to control values. In contrast, in
TZR cells, NAD levels never fully recovered over a 24-h time
period following treatment with either 0.5 or 1.5 mM TM.
Similar results were obtained in MNNG-treated cells (see
Figure 4A-C). The WT cells showed a similar overcompensation
in NAD recovery at 2.5 ,UM MNNG, albeit at the earlier time
of 8 h, and the TZR cells again showed a delayed recovery (e.g
5 gM MNNG, see 4B) or, in the case of 10 ,UM MNNG (4C), a
complete inability to recover NAD levels at all.
DNA strand break levels
A 1-h TM treatment resulted in a concentration-dependent
increase in DNA strand break levels in both cell lines (Figure SA).
There was a small increase in the net levels of DNA strand breaks
per TM dose in the TZR cell line compared with the WT, but this
was not significant at concentrations > 500 gM. Co-incubation ofa
fixed concentration of TM (150 gM) with increasing concentra-
tions of NU1025 resulted in increasing RE values for both cell
lines (Figure SB), indicating that NU1025 retarded DNA strand
break rejoining. The RE values for the TZR cells were initially
higher than the WT in the absence of NU1025, confirming the
results in Figure SA, and increased at a faster rate with increasing
concentration ofNU1025 compared with the WT cells. The slopes
were significantly different, with values of 0.218 ± 0.018
(r2 = 0.911) (TZR) and 0.166 ± 0.013 (r2 = 0.93) (WT). NU1025
treatment itself (300 gM for 24h) did not cause DNA strand
breakage (results not shown).
Regulation of NMNAT activity
We reasoned that, because of the dramatic increase in the catabo-
lism of NAD in response to DNA damage, increases in NAD
biosynthetic activity, mediated forexample by increases in NMNAT
levels (e.g. by transcriptional induction) or activity [e.g. post-trans-
lational modification by phosphorylation or poly(ADP-ribosyla-
tion)], could be important in the regulation of NAD metabolism.
This was suggested by the observation that, after low doses of
MNNG or TM, there was a time-dependent depletion of NAD
followed by a recovery to greater than control levels (see Figures
3B and 4B).
Levels of NMNAT activity in cell extracts were examined from
cells treated with MNNG in the presence or absence of 100 gM
NU1025 (see Table 2). In cells treated with high concentrations of
MNNG (10,M) for up to 4 h, although there was a slight increase
in NMNAT activity compared with control (untreated) cells at 1 h
followed by a decrease at later times, there was no significant trend.
DISCUSSION
Cells can lose 2 95% ofNMNAT function with only a consequent
approximate 50% depletion in NAD levels, indicating that during
normal, unstressed growth the reserve capacities of this enzyme
and its product NAD are well in excess of requirements. NAD
performs pleiotropic and essential cellular functions, both as a
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co-factor in oxidation-reduction reactions and as a substrate for
poly- and mono-ADP-ribosylation reactions. However, it is well
established that the majority of NAD (>90%) is confined to the
nucleus, and its turnover is accounted for by poly(ADP-ribose)
synthesis (Rechsteiner et al, 1976).
Because NMNAT is an enzyme that must respond to sudden
increases in demands on its activity following DNA damage, we
reasoned that its activity might be modulated [e.g. by post-transla-
tional modification by poly(ADP-ribosylation)] in response to
DNA damage. Emanuelli et al (1992) observed that high concen-
trations of ADP-ribose inhibited NMMAT. However, no evidence
for this was found after MNNG treatment, in either the presence or
absence ofNU1025 (see Table 2).
Compared with WT, the TZR cell line was more sensitive to the
growth-inhibitory effects of both TM and MNNG, particularly
above concentrations that caused a 2 50% NAD depletion, and
which took up to 24 h to recover (e.g. 4 or 5 gM MNNG). This
suggests that the causative cytotoxic mechanism may involve an
irreversible NAD depletion (see also discussion below).
The TZR cell line is approximately two- to three-fold more
sensitive to the chemopotentiating effects of NU1025 when used
in conjunction with either TM or MNNG. This differential sensi-
tivity can be explained most plausibly by a more effective compet-
itive inhibition of PADPRP by NU1025 in intact cells because of
reduced levels of endogenous NAD (approximately 60% of WT)
in the TZR cell line competing for binding to the active site of the
enzyme. Note that this markedly enhanced sensitivity of the TZR
cell line cannot be explained by an alteration in either the activity
ofPADPRP (which was only approximately 20% lower than WT),
although this could be a contributing factor, or its sensitivity to the
inhibitor (e.g. by mutation), as the IC50 value of NU1025 for
inhibition of PADPRP in the in vitro enzyme assay was not
significantly different in the two cell lines (see Table 1).
Consistent with the above interpretations is the observation that
an analogous increase in the sensitivity to NU1025, in this case
relating to its ability to increase net DNA strand break levels in
TM-treated cells, was observed in the TZR cell line compared with
WT. The slight increase, compared with WT, in DNA strand break
levels in TZR cells treated with TM alone suggests that PADPRP
function may be compromised by the low substrate levels in the
TZR cells.
In marked contrast, the lack of a differential sensitivity between
the two cell lines to NU1025 when used by itself indicates that
these cytostatic effects [obtained only at much higher concentra-
tions (approximately tenfold) than required forchemopotentiation]
are not due to inhibition of PADPRP. Presumably a secondary
metabolic effect ofthis compound becomes manifest at millimolar
concentrations.
Although NAD levels were approximately 50% lower in TZR
cells than WT, both cell lines demonstrated proportionate dose-
and time-dependent depletions in NAD levels after treatment with
TM or MNNG. However, because the TZR cell line had lower
control levels ofNAD to start with, the extent ofthe depletion was
much more severe. For example, 5 ,UM MNNG reduced NAD
levels from approximately 6070 to approximately 4512 pmol mg-1
protein by 6 h in WT cells, and from approximately 3678 to
approximately 1441 pmol mg-' protein in TZR cells. Thus, TZR
cells attained a nadir of 24% of WT NAD levels compared with
74% for WT cells. Furthermore, WT cells recovered normal NAD
levels by 8 h, but TZR cells had still not recovered normal levels
by 16 h. At higher doses of MNNG (10gM), TZR cells were
completely unable to recover NAD levels from a nadir of
280 pmol mg-1 protein over a 24-h time period, whereas the WT
cells did. These results are consistent with the low levels of
NMNAT in the TZR cell line becoming rate limiting for NAD
synthesis under conditions of high levels of DNA damage. A
similar pattern of results, although not so extreme, was obtained
with TM-treated cells. These data suggest that an irreversible
NAD depletion, leading to cell death (Berger, 1985), may
contribute to the enhanced cytotoxicity of MNNG and TM alone
to TZR cells, observed particularly at higher doses of the drugs.
Tumour tissues of a variety of types have been shown to have
lower NAD levels than homologous normal tissue (Jedeiken and
Weinhouse, 1955; Glock and Mclean, 1957). Hypoxic tumour
cells have increased cellular NADH/NAD ratios, which can
reduce available NAD levels at least three-fold (Wilson et al,
1977). In addition, NADH will act as a potent inhibitor of
PADPRP (Ueda et al, 1982) with a Kj value of 5 JM (in the same
range as 3-aminobenzamide, Kj 1.8 gM, Purnell and Whish, 1980).
Studies have indicated that NMNAT activity can vary widely (up
to ten-fold) in different cell lines (Ahluwalia et al, 1984), and
early, carefully performed studies in mice showed a large reduc-
tion in NMNAT activity in a number of tumour types compared
with normal tissue (Branster and Morton, 1956). Taken together,
these lines of evidence suggest that tumours are likely to have low
NAD levels compared with normal tissue.
Modulation of PADPRP activity as a therapeutic strategy is a
two-edged sword. On the one hand, extreme PADPRP activation
promotes irreversible NAD depletion; on the other hand, PADPRP
inhibition inhibits repair while maintaining NAD and ATP pools.
The effects that prevail as determinants of cytotoxicity depend on a
number of factors. Examples of such factors include initial NAD
levels, which are rapidly attenuated by nutritional deprivation of
niacin (Fu et al, 1989) and may vary widely in different tissue and
tumour types (see above). Furthermore, the dependence on PADPRP
function and normal NAD levels for the nucleosomal DNA frag-
mentation and ensuing apoptosis (Wright et al, 1996; Yoon et al,
1996), as well as the specific proteolytic cleavage of PADPRP
(Kaufmann et al, 1993), indicate an important role for PADPRP in
programmed cell death caused by chemotherapeutic agents.
We have demonstrated that cellular PADPRP function is readily
attenuated by modest changes in NAD concentration, such as
probably occur in solid tumours, or by nutritional deprivation of
niacin. This reduces the cellular capacity to survive and repair
DNA damage and, importantly, sensitizes cells to the chemopoten-
tiating effects ofPADPRP inhibitors.
These data provide a rationale for targeting PADPRP function
or NAD synthetic enzymes as potentially selective chemothera-
peutic strategies for solid tumours. Furthermore, the development
of collateral sensitivity to TM and PADPRP inhibitors in
TZ-resistant tumours would present the opportunity for 'Yin
Yang' chemotherapy, as postulated by Cheng et al (1983).
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ABBREVIATIONS
IC50, concentration that reduces growth/activity by 50%; MNNG,
1-methyl-3-nitro-1-nitroso-guanidine; NMNAT, nicotinamide
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mononucleotide adenylyltransferase; PADPRP, poly(ADP-ribose)
polymerase; RE, relative elution; TM, temozolomide; TZ, tiazo-
furin; TZR, tiazofurin resistant; WT, wild type.
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